NCT04713033

Brief Summary

The long-term goal is to transform the diagnosis and treatment of dysphonia by elucidating cervical and cranial neuromuscular mechanisms underlying typical and disordered voicing. The overall objective of this application is to propose and evaluate a novel objective spectrotemporal diagnostic tool measuring functional cervical-cranial muscle network activity in typical and disordered speakers.The purpose of this study is to improve our understanding of how the vocal tract and the muscles of the larynx and the head work at baseline and after vocal fatigue.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
14

participants targeted

Target at below P25 for all trials

Timeline
Completed

Started Sep 2021

Shorter than P25 for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

January 14, 2021

Completed
5 days until next milestone

First Posted

Study publicly available on registry

January 19, 2021

Completed
8 months until next milestone

Study Start

First participant enrolled

September 9, 2021

Completed
9 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

May 25, 2022

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

May 25, 2022

Completed
Last Updated

May 1, 2025

Status Verified

April 1, 2025

Enrollment Period

9 months

First QC Date

January 14, 2021

Last Update Submit

April 28, 2025

Conditions

Outcome Measures

Primary Outcomes (3)

  • Change in Pitch and Loudness levels in vocal tasks

    Both at baseline and after a vocal loading task, muscle network activity using sEMG will be measured in a variety of vocal tasks outlined above in Table 1 to explore the muscle network across different vocal demands and pitch and loudness levels. The pitch and loudness of each task produced at baseline by each participant will be calculated, and visual feedback will be provided to participants using the Real-Time Pitch module of the Computerized Speech Lab (Pentax, Montvale, NJ) to help them reproduce similar pitch and loudness levels during post-loading recordings.

    Baseline visit, 2 week visit, 2 months visit

  • Change in Vocal loading task

    After baseline sEMG measurements, vocal fatigue will be induced using a vocal loading task of reading in the presence of 70-dB background noise, as described in Sundarrajan 51 The duration of reading that induces self-perceived vocal fatigue varies among vocally-healthy individuals.52 Therefore, we will use the CR10 Physical Exertion Scale adapted for vocal effort to have participants rate their self-perceived participant reported

    Baseline visit, 2 week visit, 2 months visit

  • Change in Phonatory Effort (PPE)

    Phonatory Effort (PPE) while reading the first section of "The Rainbow Passage" at up to four time points during the load task. The vocal loading task will end after participants report an increase of at least 2 points in PPE.

    Baseline visit, 2 week visit, 2 months visit

Study Arms (3)

Vocally Healthy Controls

Patients will undergo a single experiment to quantify cervical-cranial muscle network patterns during vocal tasks at baseline and after a vocally fatiguing vocal loading task (loud reading) and typical swallowing task.

Diagnostic Test: surface electromyogram (sEMG)Diagnostic Test: flexible laryngoscopy

Muscle Tension Dysphonia Patients

Patients with muscle tension dysphonia will be measured at baseline and approximately 2 months after their baseline visit following a standard course of voice therapy.

Diagnostic Test: surface electromyogram (sEMG)

Unilateral Vocal Fold Paralysis Patients

Patients with unilateral vocal fold paralysis will be measured at baseline approximately 2 weeks after receiving a vocal fold medialization injection.

Diagnostic Test: surface electromyogram (sEMG)

Interventions

A device that measures electrical signals from your skin will be connected to those stickers and will make a graph that is characteristic to your vocal function.

Also known as: Trigno Wireless Biofeedback System
Muscle Tension Dysphonia PatientsUnilateral Vocal Fold Paralysis PatientsVocally Healthy Controls
flexible laryngoscopyDIAGNOSTIC_TEST

A device that examines the throat and nasal passages. The flexible laryngoscope or "scope" consists of an eyepiece and a fiber-optic light enclosed in a thin, flexible tube. The scope looks like a strand of black spaghetti with a tiny light on the end of it. The scope is inserted through the nose, and can be moved around to help the doctor see all areas of the nasal passages and throat.

Also known as: PENTAX Medical ENT Video Imaging System
Vocally Healthy Controls

Eligibility Criteria

Age18 Years - 88 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

There will be four cohorts of subjects in the study: * Cohort one will comprise vocally healthy controls * Cohort two will comprise patients with Muscle Tension Dysphonia * Cohort three will comprise patients with unilateral vocal fold paralysis

You may qualify if:

  • Experimental Group
  • Age \>18 years;
  • Patient cohorts diagnosed with muscle tension dysphonia with a recommended treatment of voice therapy.
  • Patient cohorts diagnosed with unilateral vocal cord paralysis with a recommended treatment of vocal fold injection medialization.
  • Willingness to complete all clinical/research assessments
  • Ability to give informed consent
  • (Control Group)
  • Age \>18 years;
  • Absence of any organic vocal lesion as determined on flexible laryngoscopy.
  • Willingness to complete all clinical/research assessments
  • Ability to give informed consent

You may not qualify if:

  • Experimental Group:
  • Any contraindication for wearing the device, such as a known or reported (at any time including during the study):
  • allergy;
  • history of head and neck surgery in the past 3 months;
  • presence of open wound or/and ulcer in close proximity to sEMG sensors;
  • 'smart' implant with a microcontroller (such as a pain pump or nerve stimulator);
  • participation in additional clinical research studies using investigational treatments.
  • Control group:
  • Any contraindication for wearing the device, such as a known or reported (at any time including during the study) allergy;
  • Abnormal laryngeal structure and function as determined via laryngeal endoscopic exam;
  • History of head and neck surgery in the past 3 months;
  • Presence of open wound or/and ulcer in close proximity to sEMG sensors;
  • 'Smart' implant with a microcontroller (such as a pain pump or nerve stimulator);
  • Participation in additional clinical research studies using investigational treatments.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

NYU Langone Health

New York, New York, 10016, United States

Location

MeSH Terms

Conditions

Dysphonia

Interventions

Electromyography

Condition Hierarchy (Ancestors)

Voice DisordersLaryngeal DiseasesRespiratory Tract DiseasesOtorhinolaryngologic DiseasesNeurologic ManifestationsNervous System DiseasesSigns and SymptomsPathological Conditions, Signs and Symptoms

Intervention Hierarchy (Ancestors)

ElectrodiagnosisDiagnostic Techniques and ProceduresDiagnosisMyography

Study Officials

  • Aaron Johnson

    NYU Langone Health

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

January 14, 2021

First Posted

January 19, 2021

Study Start

September 9, 2021

Primary Completion

May 25, 2022

Study Completion

May 25, 2022

Last Updated

May 1, 2025

Record last verified: 2025-04

Data Sharing

IPD Sharing
Will share

All of the individual participant data collected during the trial, after deidentification.

Shared Documents
STUDY PROTOCOL, SAP
Time Frame
Beginning 9 months and ending 36 months following article publication or as required by a condition of awards and agreements supporting the research.
Access Criteria
The investigator who proposed to use the data Upon reasonable request. Requests should be directed to achlae01@nyu.edu. To gain access, data requestors will need to sign a data access agreement.

Locations